ISSN 1662-4009 (online)

ey0015.9-2 | Late consequences of tumour therapy: prevention and monitoring | ESPEYB15

9.2 Anthropometry in Long-Term Survivors of Acute Lymphoblastic Leukemia in Childhood and Adolescence

L Collins , L Beaumont , A Cranston , S Savoie , T Nayiager , R Barr

To read the full abstract: J Adolesc Young Adult Oncol. 2017;6:294-298The difficulties in defining obesity in childhood cancer survivors have been emphasised. In these patients, body mass index (BMI) has been confirmed to be a poor predictor of body fatness, because of their impaired linear growth, body composition changes (decreased lean mass and fat redistribution) and abdominal adiposity. Th...

ey0015.9-9 | Growth, growth hormone and puberty in chronic diseases: novel insights from clinical practice | ESPEYB15

9.9 Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration

C Bizzarri , A Lonero , M Delvecchio , L Cavallo , MF Faienza , M Giordano , L Dello Strologo , M Cappa

To read the full abstract: J Endocrinol Invest. 2018;41:325-331Growth failure is common in children with chronic kidney disease (CKD) and has a multifactorial etiology. The hypothalamus-pituitary axis is intact, but there is a resistance to growth hormone (GH) action in target tissues, secondary to decreased density of GH receptors, impaired signal transduction and reduced levels of free insu...

ey0020.1-7 | Congenital Hypothyroidism | ESPEYB20

1.7. Comorbidity in congenital hypothyroidism - A nationwide population-based cohort study

E Danner , J Jaaskelainen , L Niuro , H Huopio , H Niinikoski , L Viikari , J Kero , R Sund

Brief summary: Patients with congenital hypothyroidism have a higher rate of comorbidities in adult age (1). This nationwide population-based register study aimed at investigating the incidence of comorbidities present at birth or acquired during childhood in patients with congenital hypothyroidism and prescription of specific drugs (antidepressants, antipsychotics, medication for ADHS).The study analyzed data from n=438 full-term patients with ...

ey0018.2-22 | Fetal and Neonatal Cortisol and Growth Hormone Physiology | ESPEYB18

2.22. The utility of a random growth hormone level in determining neonatal growth hormone sufficiency

L Mamilly , AL Pyle-Eilola , M Chaudhari , RK Henry

Clin Endocrinol (Oxf). 2021 Mar;94(3):392–398. doi: 10.1111/cen.14364. PMID: 33140844.In this retrospective study, random growth hormone (GH) levels were compared between newborns (mean age 9.07±6.6 days) with or without GH deficiency. A cut off of 4.5 ng/ml was established as the GH value to diagnose congenital GH deficiency. This value had a 100% sensitivity and 85% specificity for d...

ey0018.4-7 | Growth Hormone Therapy: Safety | ESPEYB18

4.7. Association of childhood growth hormone treatment with long-term cardiovascular morbidity

A Tidblad , M Bottai , H Kieler , K Albertsson-Wikland , L Savendahl

JAMA Pediatr. 2021;175(2):e205199. doi: 10.1001/jamapediatrics.2020.5199. PMID: 33346824This nationwide population-based study assessed the long-term risk of cardiovascular events in patients who had received rhGH therapy during childhood and adolescence. The study cohort comprised 3.408 subjects treated under the GHD, SGA or ISS indications, and 50 036 age-, sex-, and region-base...

ey0018.8-12 | New Concerns | ESPEYB18

8.12. First-Trimester prenatal dexamethasone treatment is associated with alterations in brain structure at adult age

A Van't Westeinde , L Karlsson , A Nordenstrom , N Padilla , S Lajic

J Clin Endocrinol Metab. 2020; 105(8):dgaa340.https://pubmed.ncbi.nlm.nih.gov/32497228/Here, the authors investigated whether prenatal treatment with dexamethasone (DEX) in the first trimester is associated with alterations of brain morphology on MRI scans. Observed MRI alterations were not linked to any alterations in cognitive function or mood, but were associated with DNA methylation in ...

ey0019.1-14 | Clinical Papers | ESPEYB19

1.14. The necessity of magnetic resonance imaging in the evaluation of pediatric growth hormone deficiency: Lessons from a large academic center

L Mamilly , AL Pyle-Eilola , M Chaudhari , RK Henry

Growth Horm IGF Res. 2021;60-61:101427. doi: 10.1016/j.ghir.2021.101427. PMID: 34592640.Brief Summary: This retrospective chart review describes abnormalities on Magnetic resonance imaging (MRI), according to severity of growth hormone deficiency (GHD) in children. MRI of the pituitary gland is recommended following the diagnosis of GHD. In prior studies, provocative...

ey0019.2-3 | Neonatal hypoglycaemia | ESPEYB19

2.3. Continuous glucose monitoring in the management of neonates with persistent hypoglycemia and congenital hyperinsulinism

M Win , R Beckett , L Thomson , A Thankamony , K Beardsall

J Clin Endocrinol Metab. 2022 Jan 1;107(1):e246-e253. doi: 10.1210/clinem/dgab601. PMID: 34407200.Brief Summary: This retrospective single center study in neonates with hyperinsulinaemic hypoglycaemia examined the utility of real-time continuous glucose monitoring (CGM). CGM is best placed as an adjunct to routine intermittent blood glucose monitoring, providing information on glucose trends d...

ey0017.3-3 | Thyroid development | ESPEYB17

3.3. Glis3 as a critical regulator of thyroid primordium specification

G Rurale , F Marelli , P Duminuco , L Persani

To read the full abstract: Thyroid. 2020;30:277–289.GLIS3 gene mutations are associated with a syndrome that combines neonatal diabetes and congenital hypothyroidism due to thyroid dysgenesis [1]. Glis3 knockout mouse models showed functional deficits of thyroid hormone synthesis but were not able to shed light on the role of Glis3 during thyroid organogenesis resulting in thyroid dysgenesis. Rurale et al.</em...

ey0017.4-5 | Important for clinical practice | ESPEYB17

4.5. Growth and adult height in girls with Turner syndrome following IGF-I titrated growth hormone treatment

AC Wang , CP Hagen , L Nedaeifard , A Juul , RB Jensen

To read the full abstract: J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa274.This retrospective study evaluated the long-term effects of GH treatment (median duration 6.7 years) in 63 girls with Turner syndrome (TS) whose GH doses were titrated to maintain IGF-I levels within the normal range. The median GH dose to maintain normal IGF-I levels was 33 (g/kg/day. Across all TS karyotypes, IGF-I titrated GH dosing led to a median adult height (AH)...